Resorantel: a dual-targeting therapeutic with potent efficacy against Staphylococcus aureus with low potential for drug resistance.

Authors

Pengfei She, Shaowei Guo, Dan Xiao, Guanqing Huang, Yiqing Liu, Mengna Li, Lihua Lu, Yelan Hong, Yong Wu

Published in

Communications biology. Jul 02, 2026. Epub Jul 02, 2026.

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a significant public health concern. The biofilm formation capability of MRSA is often associated with high levels of antimicrobial resistance. Therefore, the development of novel therapeutic strategies to combat MRSA is urgently warranted. By drug repurposing, resorantel, originally developed as an antiparasitic agent, has demonstrated significantly bactericidal activity against MRSA and its biofilms with effectively inhibitory activity against the emergence of drug resistance. Furthermore, resorantel displayed significant in vivo antibacterial efficacy in both topic and systemic infection models. Mechanistic investigations employing transcriptomics, fluorescent probes, molecular dynamics simulations, and surface plasmon resonance analysis revealed that proton motive force and MurB are likely the potential targets of resorantel. Collectively, this study identifies resorantel as a promising novel antimicrobial agent with potential for use in the treatment of MRSA and its biofilm-related infections.

PMID:
42393383
Bibliographic data and abstract were imported from PubMed on 03 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.